Pratima Chowdary, MD, MRCP, FRCPATH

Pratima Chowdary, MD, MRCP, FRCPATH
Royal Free Hospital
London, UK

Pratima Chowdary is professor of Haemophilia and Haemostasis at University College London and Haemophilia Centre Director at the Katharine Dormandy Haemophilia & Thrombosis Centre at the Royal Free Hospital in London, United Kingdom.

She has completed her medical training at Osmania University in India and NTR Health University in India, followed by subspecialty training in Hematology in Cardiff and London. She has been a consultant haematologist for more than 15 years and specializes in the management of patients with inherited and acquired bleeding and thrombotic disorders. Dr. Chowdary’s research interests lie in developing strategies for improving personalized management of haemophilia and clinical outcomes. She has served as the chief investigator for a number of academic and commercial clinical trials, including gene therapy and other novel treatments for severe haemophilia. Dr. Chowdary has overseen the development of a biobank at the Royal Free Hospital and has a special interest in biomarkers for joint disease, and novel assays for bleeding diathesis and thrombotic tendency.

She has authored more than 100 peer-reviewed publications, including three textbook chapters and has served as chair of working parties, data safety monitoring boards, and trial steering committees. She has also served as a panel member for the National Institute for Health Research, Health Technology Assessment Program in the UK and Norway. Dr. Chowdary is chair of the UK Haemophilia Centre Doctors Organization and co-director of the UK National Haemophilia Database. She is a member of numerous professional societies, including the International Society on Thrombosis and Haemostasis, British Society of Haemostasis and Thrombosis, European Association of Allied Bleeding disorders, and the World Federation of Haemophilia.


Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL